+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026

  • ID: 5456776
  • Report
  • October 2021
  • Region: Global
  • 150 Pages
  • Kuick Research
UP TO OFF
until Jan 31st 2022

FEATURED COMPANIES

  • Arog Pharmaceuticals
  • Bayer
  • Boehringer Ingelheim
  • Deciphera Pharmaceuticals
  • Gilead Sciences
  • Tyrogenex

Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data Highlights:

  • Research Methodology
  • Global & Regional Market Analysis
  • Global PDGFR Inhibitors Market Opportunity Assessment: > USD 4 Billion
  • Market & Drug Sales Insight 2020 Till 2026
  • Approved Drug In Market: 2 (Qinlock  & Ayvakit)
  • Approved PGDFR Drug Patent, Price & Sales insight 2020 Till 2026
  • Future market Assessment By Indication & Region Till 2026
  • Ongoing Clinical Trials Assessment by Status, Phase & Region
  • Key Market Dynamics
  • Competitor Landscape

Platelet derived growth factor (PDGF) are the members of growth factor receptors which are found to be overexpressed in many cancers, correlating with reduced overall survival. In some cancer types, PDGF receptors are expressed on non-cancerous cells of the tumor microenvironment or tumor stroma that are able to crosstalk with cancer and thus have critical role in the development of cancer. Over the time, it has emerged out to be an important target for the drug therapies intended for treatment wide range of cancers. 


Avapritinib sold under brand name Ayvakit is the first approved PDGFR inhibitor available in market. The drug was developed by Blueprint Medicines and is mainly indicated for the treatment of gastrointestinal tumors (GIST) and mastocytosis. The FDA approval of Ayvakit represents a major breakthrough in the treatment of rare GIST. Since it introduction into the market, the drug has shown high adoption rates among patients worldwide. The rise in prevalence of cancer and high medical needs for targeted therapy associated with increasing awareness regarding the availability of drug will further enhance its growth in market for next few years. 


In the same year, Ripretinib sold under brand name Qinlcok has also gained approval. The drug is developed by Deciphera Pharmaceuticals and is indicated for the treatment of gastrointestinal tumors. In short span of time, the drug has shown robust sales in the global market. Owing to its high specificity towards PDGFR and ability to target broad spectrum of kinases, it is expected that the drug will dominate the overall PDGFR inhibitor market in coming years. Although the market is poised to growth in coming years but several factors limits their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years.


Presently, several companies including well-established players and new entrants are actively engaged in developing PGFR inhibitors for a wide range of disease indications. Innovation in this field is mostly focused on improving the therapeutic efficacy, safety, and overall survival rate. This sector has particularly gained significant attention from private and public investors, which have extended their financial support to capable developer companies. The market also witnessed substantial partnership activity over the last few years. 


In coming years, the global market will witness significant rise in the prevalence of cancers attributing to several factors including rising geriatric population, smoking, drinking, physical inactivity, and poor diet. This will increase the demand of targeted therapies, thus driving the growth of PDGFR inhibitor market. In addition to two approved drugs, the pharmaceutical companies have developed several potential PGFR inhibitors including Crenolanib, Tovetumab, Seralutinib, ARRY-768, CP-673451, and MTLH001 which are expected to enter the market during the forecast period, thus boosting the growth of market. 


As per report findings, the global PDGFR inhibitor market will grow with CAGR of 92% and is expected to reach around US$ 4 Billion by 2026. The high growth in the market can be justified by the extensive research and development in this sector and high adoption rates of approved drugs. In addition to this, the rising initiative by government and the development of favorable reimbursement policies will also ensure the high uptake of the drug in the market. Regionally, US is expected to dominate the market owing to large target population base, increasing adoption rates to novel therapies, and high concentration of pharmaceutical companies which actively indulge in research and development sector. Apart from this, Asia-Pacific region is also expected to exhibit high CAGR rates due to increased healthcare spending and presence of several untapped opportunities.


Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Arog Pharmaceuticals
  • Bayer
  • Boehringer Ingelheim
  • Deciphera Pharmaceuticals
  • Gilead Sciences
  • Tyrogenex

1.  Introduction to PDGFR Inhibitors
1.1 Overview
1.2 Evolution of PDGFR Inhibitors


2.  PDGFR Inhibitors - Mechanism of Action
2.1 General Functions & Mechanism
2.2 Approved Drugs Mechanism of Action


3.  PDGFR Potential Target for Leading Pathological Conditions


4.  Role of PDGFR Inhibitors in Cancer


5.  Global PDGFR Inhibitors Clinical Trials Insight
5.1 By Phase
5.2 By Development Status
5.3 By Region


6.  Global PDGFR Inhibitor Market Insight
6.1 Market Overview
6.2 Current Market Scenario


7.  PDGFR Inhibitor Regional Market Analysis
7.1 US
7.2 Europe
7.3 China
7.4 Japan
7.5 ROW


8.  PDGFR Inhibitor Market Opportunity By Indication
8.1 Gastrointestinal Stromal Tumors
8.2 Glioma
8.3 Colorectal Cancer
8.4 Leukemia
8.5 Lung Cancer


9.  Lartruvo (Olaratumab) 1st Approved PDGFR Inhibitor (2016) & Market Withdrawal (2019)
9.1 Overview
9.2 Dosage, Price & Sales Analysis


10.  Ayvakit (Avapritinib) 2ND Approved PDGFR Inhibitor (2020)
10.1 Overview
10.2 Patents & Assignees


11.  Ayvakit Commercial Insight
11.1 Price & Dosage
11.2 Sales Analysis


12.  Qinlock (Ripretinib) 3rd Approved PDGFR Inhibitor (2020)
12.1 Overview
12.2 Patents & Assignees


13.  Qinlock Commercial Insight
13.1 Price & Dosage
13.2 Sales Analysis


14.  PDGFR Inhibitors Sales Forecast 2026
14.1 Ayvakit Sales Forecast
14.2 Qinlock Sales Forecast


15.  PDGFR Inhibitor Future Market Perspectives


16.  Global PDGFR Inhibitors Market Dynamics
16.1 Market Drivers
16.2 Market Challenges


17.  Competitive Landscape
17.1 Arog Pharmaceuticals, Inc
17.2 AstraZeneca
17.3 Bayer
17.4 Blueprint Medicine
17.5 Boehringer Ingelheim
17.6 Clovis Oncology
17.7 Deciphera Pharmaceuticals
17.8 Eli Lilly
17.9 Gilead Sciences
17.10 Pfizer
17.11 Tyrogenex
17.12 Zai Lab


List of Tables


Table 4-1: Frequency of PDGFR by Cancer Types
Table 8-1: Global - Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in GIST, 2021 - 2026
Table 8-2: Global - Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Glioma, 2021 - 2026
Table 8-3: Global - Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Metastatic Colorectal Cancer, 2021 - 2026
Table 8-4: Global - Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Acute Myeloid Leukemia, 2021 - 2026
Table 8-5: Global - Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Lung Cancer, 2021 - 2026


Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Arog Pharmaceuticals
  • AstraZeneca
  • Bayer
  • Blueprint Medicine
  • Boehringer Ingelheim
  • Clovis Oncology
  • Deciphera Pharmaceuticals
  • Eli Lilly
  • Gilead Sciences
  • Pfizer
  • Tyrogenex
  • Zai Lab
Note: Product cover images may vary from those shown